Rick E Winningham brings his impressive industry knowledge and business acumen to Jazz’s Board. He is a member of Biotechnology Industry Organization’s board of directors and serves on the Health Section Governing Board Standing Committee on Reimbursement, has served as a director for a state-wide trade association as well as having been president of a major Oncology/Immunology/Oncology Therapeutics network. Additionally, the combination of Mr. Winningham’s biopharmaceutical background with his business experience makes him a versatile and insightful member of our Board.
Mr. Winningham has served as a member of our board of directors since May 2010. In May 2014, Mr. Winningham was appointed as Lead Independent Director of our board of directors. Mr. Winningham has served as Chairperson of the board of directors of Theravance Biopharma, Inc., a biopharmaceutical company, since July 2013. He has served as Chief Executive Officer of Theravance Biopharma, Inc. since its spin-off from Innoviva, Inc. in June 2014. From October 2001 to August 2014, Mr. Winningham served as Chief Executive Officer of Innoviva, Inc., where he also served as Chairperson of the Board of Directors from April 2010 to October 2014. He serves as Chairperson of Retrotope, Inc., a private biotechnology company focused on cell degeneration. From 1997 to 2001, he served as President of Bristol-Myers Squibb Oncology/Immunology/Oncology Therapeutics Network and, from 2000 to 2001, as President of Global Marketing. He previously served as a member of the board of directors of OncoMed Pharmaceuticals, Inc. from June 2015 until the company’s merger with Mereo BioPharma Group plc in April 2019. He also served as a member of the board of directors of the California Healthcare Institute, or CHI, from November 2011 to March 2015 and served as its Chairperson from January 2014 until CHI merged with Bay Area Bioscience Association to become the California Life Sciences Association, or CLSA, in March 2015. Mr. Winningham is on the board of directors of CLSA, and served as its Chairperson from March 2015 until November 2015. He also serves on the board of directors of Biotechnology Innovation Organization or BIO since 2014, where he serves on its Health Section Governing Board. Mr. Winningham holds an M.B.A. from Texas Christian University and a B.S. from Southern Illinois University.
What is Rick E. Winningham's net worth?
The estimated net worth of Rick E. Winningham is at least $1.14 million as of August 14th, 2023. Mr. Winningham owns 10,444 shares of Jazz Pharmaceuticals stock worth more than $1,138,292 as of May 19th. This net worth approximation does not reflect any other assets that Mr. Winningham may own. Learn More about Rick E. Winningham's net worth.
How do I contact Rick E. Winningham?
Has Rick E. Winningham been buying or selling shares of Jazz Pharmaceuticals?
Rick E. Winningham has not been actively trading shares of Jazz Pharmaceuticals in the last ninety days. Most recently, Rick E. Winningham sold 1,241 shares of the business's stock in a transaction on Monday, August 14th. The shares were sold at an average price of $138.16, for a transaction totalling $171,456.56. Following the completion of the sale, the director now directly owns 10,444 shares of the company's stock, valued at $1,442,943.04. Learn More on Rick E. Winningham's trading history.
Who are Jazz Pharmaceuticals' active insiders?
Jazz Pharmaceuticals' insider roster includes Paul Berns (Director), Patricia Carr (SVP), Jennifer Cook (Director), Bruce Cozadd (CEO), Patrick Enright (Director), Renée Galá (CFO), Peter Gray (Director), Robert Iannone (EVP), Finbar Larkin (SVP), Seamus Mulligan (Director), Kenneth O'Keefe (Director), Anne Oriordan (Director), Neena Patil (Insider), Samantha Pearce (SVP), Kim Sablich (EVP), Elmar Schnee (Director), Mark Smith (Director), Christopher Tovey (COO), and Rick Winningham (Director). Learn More on Jazz Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Jazz Pharmaceuticals?
During the last year, Jazz Pharmaceuticals insiders bought shares 1 times. They purchased a total of 12,000 shares worth more than $1,435,800.00. During the last year, insiders at the specialty pharmaceutical company sold shares 10 times. They sold a total of 12,870 shares worth more than $1,585,220.63. The most recent insider tranaction occured on May, 3rd when EVP Neena M Patil sold 5,000 shares worth more than $548,250.00. Insiders at Jazz Pharmaceuticals own 4.4% of the company.
Learn More about insider trades at Jazz Pharmaceuticals. Information on this page was last updated on 5/3/2024.
